Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent
DEVICE: PET MRI Imaging

Sponsor

NYU Langone Health

Collaborators

[object Object]